Keryx Biopharmaceuticals (KERX) Ramps 38% Upon Trade Resumption
Tweet
Share
E-mailGet Alerts KERX Hot Sheet
Join SI Premium – FREE
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) resumed trading and is higher by 38 percent following positive Phase 3 trial data.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nscale targets up to $3B in US IPO as soon as September - Bloomberg
- Buyout firm Vista explores $3B sale of private markets data provider Allvue - Reuters
- S&P 500 may pull back before midterms, but Citi says buy the dip
Create E-mail Alert Related Categories
Trader Talk, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
